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Background: Paediatric high grade glioma (pHGG) is a distinct biological entity to histologically similar tumours
arising in older adults, and has differing copy number profiles and driver genetic alterations. As functionally
important intragenic copy number aberrations (iCNA) and fusion genes begin to be identified in adult HGG, the
same has not yet been done in the childhood setting. We applied an iCNA algorithm to our previously published
dataset of DNA copy number profiling in pHGG with a view to identify novel intragenic breakpoints.
Results: We report a series of 288 iCNA events in pHGG, with the presence of intragenic breakpoints itself a
negative prognostic factor. We identified an increased number of iCNA in older children compared to infants, and
increased iCNA in H3F3A K27M mutant tumours compared to G34R/V and wild-type. We observed numerous gene
disruptions by iCNA due to both deletions and amplifications, targeting known HGG-associated genes such as RB1
and NF1, putative tumour suppressors such as FAF1 and KIDINS220, and novel candidates such as PTPRE and KCND2.
We further identified two novel fusion genes in pHGG – CSGALNACT2:RET and the complex fusion DHX57:TMEM178:
MAP4K3. The latter was sequence-validated and appears to be an activating event in pHGG.
Conclusions: These data expand upon our understanding of the genomic events driving these tumours and
represent novel targets for therapeutic intervention in these poor prognosis cancers of childhood.
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DNA copy number and gene expression studies have
highlighted key distinctions between high grade gliomas
(HGG) arising in childhood and far more commonly,
much later in adult life [1-4]. Indeed, recent exome-level
sequencing initiatives have conclusively shown the exist-
ence of subgroups of HGG marked by distinct driver
mutations [5], which are significantly enriched in young
children (H3F3A K27M), teenagers and young adults
(H3F3A G34R/V), and middle-aged adults (IDH1/2) [6].
Specific driving events for infants and elderly patients
remain to be elucidated, however they too represent bio-
logical sub-entities, with infants having few genomic alte-
rations [4], and elderly patients harbouring frequent
amplification of EGFR and other genomic events [2,3].* Correspondence: chris.jones@icr.ac.uk
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DNA copy level are necessarily most commonly focussed
on assessing the amplification/deletion of genes in their
entirety, and approaches to ascribe significance to geno-
mic events make use of overlapping regions across mul-
tiple samples to find genes consistently within regions of
gain/loss [7]. This approach has the result of ignoring
genes for whom the breakpoint, i.e. the specific location of
copy number change, is found within the coding regions.
Such events may be more than mere bystanders of the
“driving” aberration, and may themselves play significant
roles in tumour initiation and maintenance.
One key implication of copy number breakpoints oc-
curring within genes is the possibility of generating
novel fusions. Gene fusions can occur through both
intra- and inter-chromosomal translocations, bringing
together coding regions from two or more genes within
a single reading frame allowing expression of a novel
protein. Such gene fusions are common in cancer, butal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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haematological malignancies and selected solid tumours
such as sarcomas. Recent evidence has overturned this,
with numerous novel gene fusions being discovered in a
wide range of cancer types, exemplified by the identifi-
cation of common TMPRSS2:ERG fusions in prostate
cancer [8] and the EML4:ALK fusion in non-small cell
lung cancer [9].
The first fusion gene found in glioblastoma was the re-
arrangement located at an amplified region at chromosome
4q12, resulting in the fusing of the kinase domain of
PDGFRA with the regulatory domains of KDR (VEGFR2)
[10]. This KDR:PDGFRA was found to be activating and
tumorigenic, however to date only a single additional case
has been found, in a paediatric high grade glioma (pHGG)
[11], and thus these fusions do not represent a common
event. Another low frequency fusion has more recently
been identified in approximately 3% of adult HGG, invol-
ving FGFR1 or FGFR3 partnering with TACC1 or TACC3
[12]. These FGFR:TACC fusions have been shown to
localize to mitotic spindle poles, have constitutive kinase
activity and induce mitotic and chromosomal segregation
defects and aneuploidy [12]. The types of integrated ana-
lysis that identified these mutations have also begun to
identify more common rearrangements, such as numerous
fusions involving EGFR, the most frequently seen partner
producing the EGFR-SEPT14 fusion demonstrated to acti-
vate STAT3 signaling and confer mitogen independence
and sensitivity to EGFR inhibition [13].
Such analyses are clearly proving extremely valuable in
furthering our understanding of HGG biology and gene-
rating novel targets for therapeutic intervention. As simi-
lar approaches are yet to be undertaken in the paediatric
setting, we have applied an algorithm designed to identify
intragenic copy number breakpoints in our previously
published study of DNA copy number [4]. We identify
numerous potentially functional gene disruptions and
a novel validated complex fusion, DHX57:TMEM178:
MAP4K3.
Methods
Published DNA copy number data
We previously carried out a DNA copy number profiling
study of 100 pHGG cases on Affymetrix 500 K SNP arrays
[4]. The data have been deposited at the Gene Expression
Omnibus (GEO, www.ncbi.nlm.nih.gov/geo/) with acces-
sion number GSE19578. Copy number assignment was
carried out as per the original publication, using Affymetrix
Genotyping Analysis Software (GTYPE version 4.s) im-
proved using Bayesian Linear Model with Mahalanobis
distance classifier algorithm (BRLMM) and standard
dChipSNP normalization and model-based expression
algorithms [4]. Log2-transformed data was used for all
subsequent analysis in the present study.iCNA algorithm
We implemented the iCNA algorithm developed as part of
the GTS package under R2.11.0 (cbio.mskcc.org/~brennan)
[14]. Breakpoints are calculated according to user-defined
‘delta’ values representing shifts in log2 ratios between two
contiguous genomic regions after segmenting the copy
number data using circular binary segmentation (cbs) [15].
Using a delta of 0.4, breakpoint boundaries are identified
and errors estimated by permutation-based calculations of
neighbouring probe data. Confidence intervals are assigned
and those falling within the 95% window considered ‘high
confidence’. An estimate is calculated for the expected rate
of breaks for each gene based upon gene size and rate of
breaks per sample, with a p value obtained based upon
(observed-expected)/standard error. A corrected p value
of < 0.05 is considered significant. Manual inspection of
copy number plots was undertaken to ensure sufficient
probe coverage was present at identified loci in order to
prioritise the most convincing breakpoints. Those with
substantial gaps at either side of the break were excluded.Custom oligonucleotide array CGH
We designed two fine-tiling oligonucleotide microarrays to
cover the specific amplicons observed at chromosome
2p22.1 and 10q11.21 This was undertaken using the Agilent
custom array design tool e-Array (Agilent, Santa Clara, CA,
USA; https://earray.chem.agilent.com/), and comprised 700
probes covering 43.56–43.70 Mb on chromosome 10 and
5000 probes covering 39–40 Mb on chromosome 10 with a
median probe interval of 200 bp on 2x105K microarray.
Due to limited amount of material, DNA was whole gen-
ome amplified (WGA) using the GenomePlex® Complete
Whole Genome Amplification Kit (Sigma, Gillingham, UK)
starting with 10 ng of sample and control DNA, and follo-
wing the manufacturer’s protocol. WGA DNA was labelled
using the Agilent Genomic DNA ULS labelling kit, hybri-
dised as per manufacturer’s instructions, and scanned on
the Agilent 2505B Microarray Scanner System. Data has
been submitted to ArrayExpress with accession number
E-MTAB-2340.siRNA knockdown
siRNA was carried out using a Dharmacon SMARTpool™
(Dharmacon, Lafayette, CO, USA) against MAP4K3
(#003588) with paediatric glioma cells SF188, KNS42,
UW479, Res259 and Res186 [16] and a panel of breast car-
cinoma lines. Cells were plated and transfected 24 hours
later with siRNA using Lipofectamine RNAiMax™ (Invitro-
gen, Paisley, UK) as per manufacturer’s instructions, along-
side transfections of siControl. Twenty four hours following
transfection, cells were trypsinised and media replenished
after 48 hours and 96 hours, with cell viability assessed after
seven days using CellTiter-Glo™ Luminescent Cell Viability
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Results
Intragenic copy number breakpoints in paediatric HGG
We have previously carried out DNA copy number pro-
filing of a large series of pHGG samples using Affymetrix
500 K SNP arrays, and reported numerous genes encom-
passed within areas of focal amplification and deletion [4].
We now applied an algorithm (iCNA [14]) designed to
identify copy number breakpoints contained within the
sequence of known genes. A full schema of the analytical
process is given in Figure 1.Figure 1 Schema of iCNA algorithm applied to paediatric high grade gl
published series of 100 pHGG. From these, known copy number polymorp
normal DNA samples. After filtering for statistical significance and manual i
18 amplicons, and 2 candidate fusions were identified.This algorithm was applied to 100 pHGG and 26
matched normal DNA samples, resulting in the identifi-
cation of 1099 unique DNA copy number breaks con-
tained within gene sequences across all tumour samples
(Additional file 1: Table S1). Of these, 479 were found to
map to known regions of copy number variations found
commonly in the germlines of the general population by
cross-referencing the breakpoints with The Centre for
Applied Genomics Database of Genomic Variants [17],
leaving a total of 620 events.
These were filtered to 500 after excluding those with
p values > 0.05, and further reduced to 388 with at least
one sample harbouring a given aberration at ‘highioma. 1099 intragenic breakpoints were initially identified in a
hisms were excluded, as were these seen in a series of 26 matched
nspection of copy number plots, a series of 19 intragenic deletions,
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they were also found in at least one of the normal sam-
ples profiled, representing either technical artifacts asso-
ciated with the array platform used, or low frequency
normal copy number polymorphisms. A final list of 288
iCNA is provided in Additional file 2: Table S2.
Most pHGG samples harboured at least one iCNA
(median = 3), although seven cases were found to contain
none. Several cases were found to contain many more
aberrations (maximum= 19), though these were in the
minority (Figure 2a). The number of iCNA events per
sample was found to be prognostic in this multi-
institutional series of cases, with pHGG containing more
than 10 iCNA (n = 9) found to have a significantly poorer
survival (median = 7.8 months), and those with no iCNA a
better survival (median = 24 months) than the rest of the
tumours (median = 13.2 months) (p = 0.026, log-rank test)
(Figure 2b).
There were no differences in the number of iCNA bet-
ween grade III (n = 20, median = 3, range 0–7) and grade
IV tumours (n = 58, median = 3, range 0–19) (p = 0.456,
t-test), though the cases with the highest number of iCNA
were all grade IV glioblastoma (Figure 2c). Similarly, there
were no differences between primary tumours (n = 68, me-
dian = 3, range 0–19) and those which arose as secondaryFigure 2 Clinicopathological correlates of intragenic copy number brea
per sample in a series of 100 pHGG. (b) Kaplan-Meier plot of overall surviva
Red: more than 10 breaks per sample; Grey: rest. (c-f) Boxplot of number o
grade III; Brown: grade IV. (d) Previous radiation treatment for an earlier ma
diagnosis. Yellow: infant (<3 years old); Dark yellow: older children (>3 yearmalignancies after cranio-spinal irradiation (n = 10, me-
dian = 2.5, range 0–11) (p = 0.698, t-test) (Figure 2d).
Infants (less than 3 years at diagnosis) had significantly
fewer iCNA (n = 10, median = 2.5, range 0–6) than older
children (n = 68, median = 4, range 0–19) (p = 0.050,
t-test) (Figure 2e). Tumours with the K27M mutation in
the gene encoding the histone variant H3.3, H3F3A, har-
boured significantly more iCNA (n = 5, median = 6, range
1–16) than either G34R/V mutant tumours (n = 4, me-
dian = 4.5, range 3–7) or wild-type (n = 14, median = 3,
range 0–11) (p = 0.043, ANOVA) (Figure 2f). This was in-
dependent of location of tumour, with no differences in
number of iCNA between supratentorial GBM (n = 51)
and DIPG (n = 7, p = 0.684, t-test) (data not shown).
Intragenic amplifications and deletions
The 288 iCNA were further subjected to individual man-
ual inspection of the data plots in order to identify the
most robust copy number shifts associated with intragenic
breaks. This resulted in a list of 39 unique events in 51
samples (Table 1). The recurrent changes included copy
number loss, resulting primarily in either the absence of
the 3′ end of a gene or small deletions wholly within
the coding sequence. These intragenic deletions included
those targeting known tumour suppressors in glioblastomaks in paediatric high grade glioma. (a) Number of intragenic breaks
l stratified by number of intragenic breaks per sample. Pink: no breaks;
f intragenic breaks per sample separated by - (c) WHO grade. Orange:
lignancy. Grey: primary pHGG; Purple: post-irradiation; (e) Age at
s old). (f) H3F3A status. Blue: G34R/V; Green: K27M; Grey: wild-type.
Table 1 Nominated intragenic copy number aberration candidates
Candidate.ID Gene Chromosome Sample Copy number change Comments
1 FAF1 1 HGG091 Deletion
FAF1 1 HGG140 Deletion
2 CD84 1 HGG088 Amplification
3 LGALS8 1 HGG070 Deletion
4 KIDINS220 2 HGG077 Amplification
5 DHX57 2 HGG063 Amplification Fusion candidate
6 TMEM178 2 HGG063 Amplification Fusion candidate
7 WDR49 3 HGG010 Amplification
8 PDCD10 3 HGG157 Deletion
9 CHIC2 4 HGG077 Amplification
10 ITGA1 5 HGG029 Deletion
11 EPHA7 6 HGG139 Deletion
12 LANCL2 7 HGG060 Amplification
13 ECOP 7 HGG060 Amplification
14 KCND2 7 HGG152 Amplification
KCND2 7 HGG162 Amplification
14 SND1 7 HGG090 Deletion
15 CSMD3 8 HGG054 Deletion
CSMD3 8 HGG140 Deletion
CSMD3 8 HGG153 Deletion
16 SLC24A2 9 HGG151 Deletion
SLC24A2 9 HGG011 Deletion
17 MTAP 9 HGG022 Deletion
MTAP 9 HGG007 Deletion
18 ANKRD26 10 HGG068 Deletion
19 RET 10 HGG139 Amplification Fusion candidate
20 CSGALNACT2 10 HGG139 Amplification Fusion candidate
21 PTPRE 10 HGG086 Deletion
PTPRE 10 HGG145 Deletion
22 RAB6IP1 11 HGG092 Amplification
23 PSMA1 11 HGG092 Amplification
24 TMTC1 12 HGG010 Amplification
TMTC1 12 HGG068 Amplification
25 LRRK2 12 HGG068 Amplification
26 MYO1A 12 HGG029 Amplification
27 XRCC6BP1 12 HGG029 Amplification
28 OSBPL8 12 HGG065 Amplification
OSBPL8 12 HGG162 Amplification
29 RB1 13 HGG154 Deletion
30 PCDH17 13 HGG059 Deletion
31 CD276 15 HGG006 Deletion
32 MEF2A 15 HGG011 Deletion
33 DNAH2 17 HGG143 Amplification
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Table 1 Nominated intragenic copy number aberration candidates (Continued)
34 NF1 17 HGG154 Deletion
NF1 17 HGG140 Deletion
35 BRIP1 17 HGG077 Deletion
36 KCNB1 20 HGG139 Amplification
37 SYN3 22 HGG017 Deletion
SYN3 22 HGG146 Deletion
38 TIMP3 22 HGG146 Deletion
39 PHF21B 22 HGG072 Deletion
39 unique intragenic breakpoints found within 51 cases of paediatric high grade glioma. Direction of copy number shift (gain/loss) is reported, as well as
candidate fusion events.
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n = 1) (Additional file 3: Figure S3), as well as putative
novel GBM-associated genes including FAF1 (1p33, n = 2)
and MTAP (9p21.3, n = 2) (Additional file 3: Figure S3). In
addition, there were novel deletions in the protein phos-
phatase PTPRE (10q26.2, n = 2) (Figure 3b) and recurrent
internal microdeletions in the gene CSMD3 (CUB and
Sushi multiple domains 3) (8q23.3, n = 3), all of which
overlapped to result in the loss of exon 4 (Additional file 3:
Figure S3).
Copy number gains within gene coding regions tended
to be associated with regions flanking known oncogenic
amplicons. These included amplification of the MYCN
locus at chromosome 2p24.3, which in case HGG077
breaks within the coding region of the kinase D-interac-
ting substrate KIDINS220 (Figure 4a); amplification of
PDGFRA at 4q12, harbouring an iCNA in CHIC2 in the
same case (though only covered by two probes); and re-
current breakpoints in the gene encoding the potassium
voltage-gated channel KCND2 at 7q31.31 in association
with amplification of MET, though curiously this targeted
either 5′ or 3′ ends in two different cases (Figure 4b).
Similarly, common amplification events encompassing
EGFR (7p12) and CDK4 (12q14) had intragenic break-
points at both ends in cases HGG060 (LANCL2 and
ECOP) and HGG029 (MYO1A and XRCC6BP1), respec-
tively (Additional file 4: Figure S4).
Identification of novel fusion genes
For the most part, iCNA events resulted in an imbalance
of certain regions of coding genes in isolation, with the
predicted consequence a disruption of full-length gene ex-
pression. For certain events however, a 5′ end of one gene
was found amplified at a similar copy number to a 3′ end
of a second gene within the same case. We reasoned that
such instances may represent candidate fusion genes, and
we identified two such examples in our cohort.
The first was at chromosome 10q11.21 and reflected a
single amplicon, breaking within the genes RET and
CSGALNACT2 such that we propose a hypothetical
fusion gene encompassing the 5′ regulatory regions ofCSGALNACT2 and the 3′ kinase domain of RET. In
order to determine the precise breakpoints to allow
validation of this novel fusion, we designed custom
oligonucleotide arrays spanning the amplicon in order to
carry out high-resolution array CGH on the reference
case HGG139, a relapse sample of glioblastoma in which
this genomic event was not present in the primary tu-
mour. Although the breakpoint for CSGALNACT2 was
identified within intron 2, leaving the catalytic domains
intact, the breakpoint within RET could not be accur-
ately determined to closer than 10 kb between introns 1
and 2 (Additional file 5: Figure S5). As material was li-
mited for this case, we were unable to confirm the pre-
cise nature of the putative CSGALNACT2:RET fusion by
PCR-based techniques.
The second fusion candidate was located at an amplified
region of chromosome 2p22.1 in case HGG063, an ana-
plastic astrocytoma. At Affymetrix 500 K SNP resolution,
this appeared to be a single amplicon with breaks within
the coding regions of the RNA helicase DHX57 and the
transmembrane protein TMEM178 (Figure 5a). Applying
the same approach as above, using custom-designed oligo-
nucleotide arrays for high-resolution array CGH revealed
two amplicons within this structure, with further intra-
genic breakpoints within the mitogen-activated protein
kinase MAP4K3 (Figure 5b). Designing PCR primers to
amplify across the highly specific breakpoints confirmed
the presence of the fusion, which was further validated by
direct sequencing (Figure 6).
The resultant fusion gene, DHX57:TMEM178:MAP4K3,
is a complex three gene fusion formed from a series of in-
tragenic breaks, amplifications and inversions to produce
a sequence comprising exons 1–12 of DHX57, exons 2–4
of TMEM178 and exons 13–34 of MAP4K3, associated
with regions of microhomology (Figure 6). This would
produce a protein with the zinger finger and DEAD-like
helicase domains of DHX57, the claudin family trans-
membrane domains of TMEM178 and the citron domain
of MAP4K3. Selective knockdown of MAP4K3 by siRNA
leads to a significant reduction in cell viability in five
paediatric glioma cell lines as assayed by CellTiter Glo, an
Figure 3 Intragenic deletions in paediatric high grade glioma. (a) Recurrent copy number breakpoint within NF1 on chromosome 17q11.2 in
two cases of pHGG. (b) Recurrent copy number breakpoint within PTPRE on chromosome 10q26.2 in two cases of pHGG. Dark pink: confirmed
region of loss; Light pink: region within which breakpoint lies, as defined by the resolution of probes on the array.
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pHGG vs breast cancer, t-test) (Additional file 6: Figure S6).
Discussion
Comprehensive copy number profiling of adult and
paediatric high grade gliomas was among the first data
to demonstrate the biological differences between these
similar-looking histological malignancies [18]. In this
context, the focus has been on large-scale genomic copy
number changes. A more refined analysis of copy num-
ber and exon-level expression data has identified newinsights into genomic architecture and novel fusion pro-
teins in adult glioblastoma [12,13]. Here we leverage a
large dataset we have previously generated [4] in the
paediatric disease to carry out a scan of intragenic break-
points, leading to the identification of novel gene disrup-
tions and candidate gene fusions.
The presence of intragenic copy number aberrations
was confirmed in the vast majority of pHGG cases, and
was itself prognostic, with an absence of iCNAs confer-
ring a longer overall survival in paediatric patients. This
was associated with the infant age group, known to have
Figure 4 Intragenic amplifications in paediatric high grade glioma. (a) Copy number breakpoint within KIDINS200 on chromosome 2p25.1,
flanking the MYCN amplicon in a case of pHGG. (b) Recurrent copy number breakpoint within KCND2 on chromosome 7q31.31 in two cases of
pHGG, in both cases part of the MET amplicon, though targeting either the 5′ or 3′ end of the gene. Dark green: confirmed region of gain; Light
green: region within which breakpoint lies, as defined by the resolution of probes on the array.
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further highlights the biological distinctiveness of this
age group. By contrast, the presence of large numbers of
intragenic breaks conferred a shorter survival time, but
was not a result of the grade of the tumour, nor asso-
ciated with a second malignancy due to radiation treat-
ment for an earlier cancer. We had previously reported
an association of post-irradiated HGG with PDGFRA
amplification and chromosome 1q gain [4], so it appears
these are relatively selective radiation-induced changes,
rather than reflecting a generalised genomic instability
in secondary tumours from these patients. Importantly,
we identified an increased number of iCNA in tumours
harbouring an H3F3A K27M mutation, regardless of
anatomical location. This is a group of thalamic and
pontine HGG associated with a particularly dismal prog-
nosis [18], for whom understanding the mechanisms ofgenomic instability and the identification of novel gene
disruptions is of considerable interest.
The majority of intragenic breakpoints we identified
were associated with gene disruption. This includes dele-
tions of known tumour suppressors such as RB1 and
NF1, but also more novel glioblastoma associated genes.
FAF1 and MTAP were both recurrently targeted by in-
tragenic deletion events in pHGG. These genes are loca-
lised close to known cyclin-dependent kinase inhibitors
and tumour suppressors CDKN1C and CDKN2A/B, re-
spectively, but both FAF1 and MTAP have recently been
proposed to harbour tumour suppressor activity in their
own right. FAF1 is associated with a FAS-mediated
apoptosis response and restoration of the FAF1 protein
in adult glioma cell lines significantly increases cell death
[20], whilst in MTAP-deficient cells, methylthioadeno-
sine, generated during polyamine biosynthesis, is not
Figure 5 Identification of a novel complex fusion DHX57:TMEM178:MAP4K3. (a) Affymetrix 500 K SNP array of chromosome 2, highlighting
two amplicons, the most telomeric encompassing MYCN, the more centromeric as 2p22.1 involving intragenic breakpoints in DHX57 and
TMEM178 (green). (b) Custom oligonucleotide array of the 2p22.1 amplicon, revealing two amplified structures and three intragenic breakpoints,
in DHX57, MAP4K3 and TMEM178 (green).
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nine is absent [21]. It seems that such mechanisms are
also likely in a subset of paediatric tumours.
Of note we identified novel deletions in the protein
phosphatase epsilon, PTPRE. This has not been reported
previously, although there are several reports of the
tumour suppressive capacity of the related PTPRD
[22,23]. This gene also appears targeted by intragenic
deletions, and human astrocytes lacking PTPRD exhib-
ited increased growth, as it is thought the protein usually
functions to dephosphorylate the oncoprotein STAT3
[23]. The wholly intragenic microdeletions observed
in CSMD3 in four cases may represent another novel
mechanism of gene disruption. CSMD3 encodes a gene
with multiple CUB and Sushi domains whose function is
poorly understood. Recently, CSMD3 was identified as
the second most frequently mutated gene (next to TP53)
in lung cancer, where it was demonstrated that loss of
CSMD3 results in increased proliferation of airway epi-
thelial cells [24].Gene disruption may also play a significant functional
role when known gain-of-function oncogenes are ampli-
fied. We report numerous intragenic breakpoints which
may have been overlooked in the context of identifying
the ‘driver’ event within a common amplicon, but which
may themselves be tumorigenic. These include disruptions
of KIDINS220, a functional mediator of multiple receptor
signalling pathways and essential for cortical development
[25,26]; CHIC2, frequently deleted/rearranged in myeloid
malignancies [27]; and KCND2, encoding a potassium
voltage-gated channel, which is expressed in both neu-
ronal and glial cells and has been shown to regulate ERK
signalling in ganglioglioma [28]. All of these gene dis-
ruptions represent novel avenues for understanding the
underlying biology of pHGG.
Of most interest was the use of the iCNA algorithm to
identify potential novel fusion genes, as was demonstrated
in adult glioblastoma with the identification of the KDR:
PDGFRA fusion [10], which we also found in a case of
pHGG [11]. Our analysis nominated two potential
Figure 6 Cartoon depicting the structure of the DHX57:TMEM178:MAP4K3 fusion. A complex microhomology-mediated rearrangement of
exons 1–12 of DHX57 (blue), exons 2–4 of TMEM178 (green) and exons 13–34 of MAP4K3 (orange) was confirmed by direct sequencing. Regions
of microhomology are highlighted in grey.
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idate, CSGALNACT2:RET. Such a putative fusion would
retain the kinase domain of the RET oncoprotein, but
would lose the autoregulatory portion of the protein,
instead fusing it to the N terminal of chondroitin sulfate
N-acetyl-galactosaminyltransferase 2. Although a precise
cancer-related function has not been ascribed to the latter
enzyme, it is though to play an important role in morpho-
genesis in zebrafish models [29,30]. Whilst not validated,
oncogenic RET rearrangements and fusions are common
in thyroid and lung cancer [31,32], and the presence of in-
frequent activating fusions in HGG do not seem unlikely.
We were able to validate a novel complex fusion invol-
ving three genes with intragenic breakpoints and am-
plification/rearrangement on chromosome 2p22.1. The
resulting fusion gene, DHX57:TMEM178:MAP4K3 en-
compasses key regulatory domains from all three proteins,
though a specific function is hard to predict. The helicase
properties of the DHX57 component may be a candidate
for oncogenicity, with numerous other DEAD-box heli-
cases appearing to play a role in regulation of DNA repair,apoptosis and drug sensitivity [33]. MAP4K3 has been as-
sociated with several malignancies in both an oncogenic
and tumour suppressor capacity [34,35]. In particular, one
function that has been ascribed includes activation of
mTOR signalling via the TORC1 complex [36], a pathway
commonly activated by diverse mechanisms in pHGG [18].
In the context of pHGG, although the kinase domain
is not retained in the fusion, MAP4K3 plays some func-
tional role as selective knockdown by siRNA leads to
a significant and selective reduction in cell viability in
paediatric glioma cell lines. Thus we hypothesise that
the DHX57:TMEM178:MAP4K3 is activating as disrup-
tion of the protein would otherwise seem incompatible
with tumour cell growth and proliferation.
Conclusion
In summary these data represent a key addition to our un-
derstanding of the genomic alterations driving pHGG and
provide novel avenues for developing sorely-needed novel
therapeutic strategies for children with these otherwise in-
curable tumours.
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Additional file 1: Table S1. Initial output from iCNA algorithm detailing
1099 intragenic copy number breakpoints in 100 cases of paediatric high
grade glioma.
Additional file 2: Table S2. Final output from iCNA algorithm detailing
288 filtered intragenic copy number breakpoints in 100 cases of
paediatric high grade glioma.
Additional file 3: Figure S3. Intragenic deletions in paediatric high grade
glioma. (a) Recurrent copy number breakpoint within FAF1 on
chromosome 1p33 in two cases of pHGG. (b) Recurrent copy number
breakpoint within MTAP on chromosome 9p21.3 in two cases of pHGG.
(c) Copy number breakpoint within RB1 on chromosome 13q14.2 in a
case of pHGG. (b) Recurrent copy number breakpoint within CSMD3 on
chromosome 8q23.3 in three cases of pHGG. Dark pink: confirmed region
of loss; Light pink: region within which breakpoint lies, as defined by the
resolution of probes on the array.
Additional file 4: Figure S4. Intragenic amplifications in paediatric high
grade glioma. (a) Copy number breakpoints within LANCL2 and ECOP on
chromosome 7p11.2, flanking the EGFR amplicon in a case of pHGG.
(b) Recurrent copy number breakpoints within MYO1A1 and XRCC6BP1 on
chromosome 12q13.3 and 12q14.1, flanking the CDK4 amplicon in a case
of pHGG. Dark green: confirmed region of gain; Light green: region
within which breakpoint lies, as defined by the resolution of probes on
the array.
Additional file 5: Figure S5. Identification of a novel candidate fusion
CSGALNACT2:RET. (a) Affymetrix 500 K SNP array of chromosome 10,
highlighting an amplicon at 10q11.21 (green). (b) Custom oligonucleotide
array of the 10q11.21 amplicon, revealing a clear breakpoint within
CSGALNACT2 (green), but a less clear boundary within RET (grey).
Additional file 6: Figure S6. siRNA knockdown of MAP4K3 in paediatric
glioma and breast carcinoma cells. Paediatric glioma cells (green) were
highly sensitive to knockdown of MAP4K3, with 5/5 cells showing
significant effects on cell viability. By contrast, only 2/20 breast cancer
cells (blue) showed a similar dependency on MAP4K3 expression for cell
viability. The screen was carried out in three independent experiments
and was highly reproducible for all cell lines, with R2 values ranging from
0.68-0.94 (breast) and 0.78-0.92 (glioma). The different sensitivity of
glioma cells to MAP4K3 knockdown as compared to breast carcinoma
cells was statistically significant (p = 0.0017, pHGG vs breast cancer, t-test).Competing interests
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